Search

Nitric oxide (NO) is an essential biological messenger, contributing a significant role in a diverse range of physiological processes. The light-controllable NO releasers are of great interest because of their potential as agents for NO-related research and therapeutics. Herein, we developed a pair of red-light-controllable NO releasers, pfRd-C9A-{FeNO}7 and pfRd-C42A-{FeNO}7 (pfRd = Pyrococcus furiosus rubredoxin), by constructing a nonheme {FeNO}7 center within the redesigned iron-sulfur protein scaffolds. While shown to be both air and thermally stable, these complexes are highly sensitive to red-light irradiation with temporal precision, which was confirmed by electron paramagnetic resonance spin trapping and Griess assay. The temporally controlled NO release from these complexes was also demonstrated in DNA cleavage assay. Overall, this study demonstrates that such a protein-based nonheme iron nitrosyl system could be a viable chemical tool for precise NO administration.

In this paper, alkali ion (Li

The molecular clusters ((HO)3Si-O-Si(OH)3, and (HO)3Al-O-Si(OH)3 ) representative of aluminosilicate mineral surface were employed to study the dissolution of aluminosilicate in acidic condition via density functional theory with the M06-2X+G(d,p) methodology. The surface termination sites (Si and Al) were both tetra-coordinated and the terminal oxygen was protonated in acidic condition. In the dissolution reaction, the calculated barrier height of the six-membered ring transition state complex containing two water molecules was predicted to be lower than that of four-membered ring transition state complex containing one water molecule. In addition, the calculated barrier heights for Al-terminated sites were predicted to be lower than those for the Si-terminated sites, suggesting that breaking the Al-O bond is easier than Si-O bond in the aluminosilicate mineral surface; the barrier heights of the surface termination sites with protonated terminal oxygen were lower than those without protonated terminal oxygen. With the fracture of Si-O and Al-O bonds, the Si and Al release from the aluminosilicate. These results confirm the experimental conclusions that the acidic condition facilitates the release of Si and Al from the aluminosilicate, and the concentration of Al leaching from aluminosilicate is higher than Si.

The hydrazinolysis of S-cyanylated peptide provides an alternative way to afford protein α-hydrazide, a key reagent used in native chemical ligation (NCL), without the aid of any inteins or enzymes. The currently used non-selective S-cyanylation, however, allows no other cysteine in the protein besides the one at the cleavage site. Herein, we report a regioselective S-cyanylation and hydrazinolysis strategy achieved via the fusion of a tetracysteine tag to the C-terminal of the protein of interest. We term it tetracysteine enabled protein ligation (TCEPL). While highly selective, the strategy is applicable for proteins expressed as inclusion bodies, and this was showcased by the efficient semi-synthesis of an iron-sulfur protein rubredoxin and the catalytic and hinge domains of matrix metalloprotease-14 (MMP-14) containing 207 amino acid residues. Furthermore, the TCEPL strategy was exploited for protein C-terminal labeling with amino reagents bearing a variety of functional groups, demonstrating its versatility and generality.

Nitric oxide (NO) is an essential biological messenger, contributing a significant role in a diverse range of physiological processes. The light-controllable NO releasers are of great interest because of their potential as agents for NO-related research and therapeutics. Herein, we developed a pair of red-light-controllable NO releasers

A new Ni metal organic framework based on 2,2′-Biphenyldicarboxylic, 4,4′- bipyridine as linker is prepared by hydrothermal reaction and directly used as an electrode material for supercapacitor and the detection of sarcosine. [Ni3(BIPY)3(BPDA)2(HCOO)2(H2O)2]n (Ni-1, BIPY = 4,4′-bipyridine, BPDA = 2,2′-Biphenyldicarboxylate) displays the specific capacitance of the Ni-1 are 667 F/gat 1 A/g and retention is 82% of initial capacitance at 1 A/g. The excellent electrochemical property is ascribed to the intrinsic nature of Ni-1. Furthermore, the sarcosine sensing performance of the Ni-1 electrode is evaluated in 0.1 M of NaOH solution and the electrode showed a wider range of linear response 1 × 10−4M to 1 × 10−3 M. Thus, the results show that the Ni-1 is a potential candidate for not only sensing of sarcosine but also supercapacitor application.

Background There have been no reliable scientific studies examining whether the interval between induction chemotherapy (IC) and initiating radiotherapy is associated with poor outcomes of nasopharyngeal carcinoma (NPC). Patients and methods In this retrospective study, we included a total of 239 local advanced NPC patients who underwent concurrent chemoradiotherapy and IC. Based on the interval between IC and intensity-modulated radiation therapy (IMRT), the patients were classified into three groups as follows: Group A (≤7 vs >7 days), Group B (≤14 vs >14 days), and Group C (≤ 21 vs >21 days). Univariate and multivariate regression analyses were performed to determine the prognostic factors of survival outcomes. The differences between the two groups were compared by the log-rank test. Results The median IC-IMRT interval was 9 days (range, 1-76 days). The median follow-up time was 40 months (range, 4-58 months). The IC-IMRT interval including Group A, Group B, and Group C was not significantly associated with overall survival (OS), distant metastasis-free survival (DMFS), locoregional relapse-free survival (LRFS), or disease-free survival (DFS). Multivariate analysis showed that the tumor stage was the independent significant predictor for OS, DMFS, LRFS, and DFS. But it appears that there was a trend toward improvement in the outcome of ≤7 days group in OS from the Kaplan-Meier curves. Conclusion It is also feasible to postpone radiotherapy for 1-3 weeks if patients were unable to receive treatment immediately due to chemotherapy complications such as bone marrow suppression. However, we suggest that patients should start IMRT as soon as possible after IC.

6061 Background: Concurrent chemoradiotherapy (CCRT) is currently considered to be the standard treatment for locoregionally advanced nasopharyngeal carcinoma (LA-NPC), accompanied with non-neglectable toxicity and unsatisfactory compliance. Therefore, it is highly warranted to explore an alternative regimen for LA-NPC. This trial aimed to assess and investigate the efficacy and safety of recombinant human endostatin ( Rh-endostatin) with intensity-modulated radiotherapy (IMRT) for low-risk LA-NPC. Methods: Patients with low-risk LA-NPC were randomly assigned into ERT group (n=60, receiving Rh-endostatin plus radiotherapy) and CCRT group (n=60, receiving cisplatin plus radiotherapy). The primary endpoint was the 5-year overall survival (OS). Non-inferiority was shown if the upper limit of the 95% CI for the difference in 5-year OS between the ERT group and CCRT group did not exceed 15%. The secondary endpoint was 3-year progression-free survival (PFS). Results: A total of 120 patients were included in the trial. After a median follow-up of 71 months (IQR 62-75), the 5-year OS rate was 88.1% in the ERT group and 77.6% in the CCRT group, with a difference of 10.5% (95% CI: -0.03 to 0.24; Pnon-inferiority = 0.002). Patients in the ERT group had better 3-year PFS than that in the CCRT group (89.8% vs 70.6%; HR = 0.362; 95% CI: 0.150-0.873; Plog-rank = 0.018). The overall all-grade toxicity burdens were heavier in CCRT group. No patients died of treatment-related causes. Conclusions: Rh-endostatin combined with IMRT had favorable efficacy, fewer toxic effects and more improved quality of life, which might be a promising alternative regimen to CCRT for low-risk LA-NPC in clinic. Clinical trial information: NCT02237924. [Table: see text]

Background: A Phase II, randomized, prospective, multicentric trial (NCT02237924) was conducted to evaluate the efficacy and safety of Endostar plus radiotherapy in patients with low-risk local advanced nasopharyngeal carcinoma (NPC). Methods: From 09/2014 to 08/2016, patients with low-risk local advanced NPC were randomly treated with Endostar plus radiotherapy (ERT group, n=60) and concurrent chemoradiotherapy (CCRT group, n=60). Primary endpoint was the 5-year overall survival (OS) rate. The secondary endpoints were 3-year progression free survival (PFS) rate, OS rate, loco-regional recurrence free survival (LRRFS) rates and distance metastasis free survival (DMFS) rates. Findings: After a median follow-up of 47 months, 3-year OS rates were 93.2% and 79.3%, 3-year PFS rates were 89.8% and 70.6%, 3-year DMFS rates were 93.2% and 80.7%, in two groups, respectively (P 0.05). Moreover, the incidences of complications were significantly lower in ERT group. For short-term curative effects, CR rates were 70.0% and 60.0% for primary tumor, 73.3%and 65.0% for cervical lymph nodes, in two groups, respectively (P 0.05). Interpretation: OS, PFS, and DMFS rates can be improved, adverse events be reduced, with better tolerability, by Endostar plus radiotherapy, when compared to concurrent chemoradiotherapy for local advanced low-risk NPC. Trial Registration: (NCT02237924). Funding Statement: This work was supported by National Natural Science Foundation of China (No. 81760542), the Projects for Research and Development of Medical and Health Appropriate Technology of Guangxi Zhuang Autonomous Region (No. S2018087), the Key Research and Development Program of Guangxi (No. Guike AB18281003), Guangxi Medical University Training Program for Distinguished Young Scholars, and Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University, “139” Program for high-level medical talents in Guangxi, Innovation Team of the First Affiliated Hospital of Guangxi Medical University. Guangxi Science and Technology Program Project (GK AD17129013), Simcere. Declaration of Interests: The authors declare that they have no competing interests. Ethics Approval Statement: This study was approved by the Ethics Committee of Guangxi Medical University. All procedures performed in the study involving human participants were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments. Written informed consent was obtained from the patient and his/her immediate families.

A series of novel near-infrared (NIR) long persistent phosphors of Zn1.2Al1.6Ge0.2O4: Cr3+, Yb3+ was synthesized by a solid state method. The crystal structure of Zn1.2Al1.6Ge0.2O4 was identified. Yb3+ ions were effective codopants for improving the NIR persistent luminescence intensity even after 100 h of decay. The persistent luminescence decay curves and the thermo-luminescence spectra were analyzed. Results indicated that the increase in efficient electron trap concentration induced by doping Yb3+ ions was a major factor in the improvement of the NIR persistent luminescence. Moreover, short-wave infrared (SWIR = 900–1700 nm) emission of Yb3+ was be excited by UV and visible light through charge transfer transition of O2-–Yb3+ and energy transfer from Cr3+ to Yb3+, respectively.

Recent years have seen an ever increasing number of enzyme mediated protein/peptide modification reactions, which contribute significantly to the elucidation of related biological functions. The many available enzymes have, however, caused difficulties for practitioners in choosing the most appropriate enzyme for a certain purpose. This review surveyed the widely used enzymes (i.e., sortases, butelase 1, subtiligase, formylglycine generating enzyme and farnesyltransferase) in the manipulation of proteins/peptides, and the application fields of these enzymes as well as the advantages and limitations of each enzyme are summarized.

A new layer-like metal–organic framework {[Cd4(NDIC)4·5DMF·H2O]DMF}n (NDIC = 5-(5-norbonene-2,3-dicarboximide) isophthalic acid) was synthesized by solvothermal method. It was used as a parent framework to encapsulate Tb3+ cations in Cd-MOF. The obtained composite Tb(3+)@Cd-MOF exhibited excellent luminescence and produced a remarkable quenching effect in the luminescence emission of Tb3+ upon the introduction of Cr3+. Subsequently, Tb(3+)@Cd-MOF was developed as a highly selective and sensitive probe for detection of Cr3+. In particular, the luminescence probe of Cr3+ had a low detection limit (7.5 × 10−8 M), a broad linear range (1 × 10−7–5 × 10−6 M). A paper strip coated with Tb(3+)@Cd-MOF was also shown to be highly selective to Cr3+ under the irradiation of 254 nm UV light of by the naked eyes. This is the first example for detecting metal ions based on a lanthanide functionalized new metal–organic framework (MOF).

In this study, a lanthanide metal organic framework based on the ligand of terephthalic acid derived from waste polyethylene terephthalate (PET) bottles was designed and synthesized. The structure and morphology of the Tb-BDC was investigated by X-ray diffractometry (XRD), Fourier transform infrared spectroscopy (FT-IR), and scanning electron microscopy (SEM). The Tb-BDC displays a high selectivity and sensitivity towards picric acid (TNP). The luminescence intensities exhibit a linear relation, with a concentration of TNP over the range of 1 &times, 10&minus, 5&ndash, 1 &times, 4 M, with a limit of detection of 1 &times, 5 M. The sensing mechanism is also discussed. This is the first time that waste PET materials have been used as the starting precursor of terephthalic acid (BDC) for the fabrication of lanthanide MOF (metal organic framework), which is applied in sensing TNP.

Background There have been no reliable scientific studies examining whether the interval between induction chemotherapy (IC) and initiating radiotherapy is associated with poor outcomes of nasopharyngeal carcinoma (NPC). Patients and methods In this retrospective study, we included a total of 239 local advanced NPC patients who underwent concurrent chemoradiotherapy and IC. Based on the interval between IC and intensity-modulated radiation therapy (IMRT), the patients were classified into three groups as follows: Group A (≤7 vs >7 days), Group B (≤14 vs >14 days), and Group C (≤ 21 vs >21 days). Univariate and multivariate regression analyses were performed to determine the prognostic factors of survival outcomes. The differences between the two groups were compared by the log-rank test. Results The median IC-IMRT interval was 9 days (range, 1–76 days). The median follow-up time was 40 months (range, 4–58 months). The IC-IMRT interval including Group A, Group B, and Group C was not significantly associated with overall survival (OS), distant metastasis-free survival (DMFS), locoregional relapse-free survival (LRFS), or disease-free survival (DFS). Multivariate analysis showed that the tumor stage was the independent significant predictor for OS, DMFS, LRFS, and DFS. But it appears that there was a trend toward improvement in the outcome of ≤7 days group in OS from the Kaplan–Meier curves. Conclusion It is also feasible to postpone radiotherapy for 1–3 weeks if patients were unable to receive treatment immediately due to chemotherapy complications such as bone marrow suppression. However, we suggest that patients should start IMRT as soon as possible after IC.

A nickel-functionalized copper metal&ndash, organic framework (Ni@Cu-MOF) was prepared by a facile volatilization method and a post-modification synthesis method at room temperature. The obtained Ni@Cu-MOF electrode delivered a high capacitance of 526 F/g at 1 A/g and had a long-term cycling stability (80% retention after 1200 cycles at 1 A/g) in a 6 M KOH aqueous solution. Furthermore, an asymmetric supercapacitor device was assembled from this Ni@Cu-MOF and activated carbon electrodes. The fabricated supercapacitor delivered a high capacitance of 48.7 F/g at 1 A/g and a high energy density of 17.3 Wh/kg at a power density of 798.5 kW/kg. This study indicates that the Ni@Cu-MOF has great potential for supercapacitor applications.

The purpose of this study was to analyze the efficacy and safety of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma (NPC).This study included 45 N3 stage NPC patients treated with induction chemotherapy, sequential Nimotuzumab plus concurrent chemoradiotherapy. The intensity modulated radiation therapy (IMRT) doses for planning target volume (PTV) were 70-72 Gy for gross disease in the nasopharynx, and 66-70 Gy for positive lymph nodes. The doses for high risk and low risk regions PTV were 60-62 Gy and 54-56 Gy in 31-33 fractions. Induction chemotherapy consisted of 3 cycles of docetaxel (75 mg/m2, day 1) plus lobaplatin (30 mg/m2, day 1). Concurrent with radiotherapy, patients received chemotherapy consisting of lobaplatin 50 mg/m2, day 1. Targeted drug therapy given on the first time of IMRT consisted of Nimotuzumab (200mg, iv weekly for 7 courses). Cycle repetition of chemotherapy was every 21 days.The efficacy of 3 cycles of induction chemotherapy before the start of concurrent chemoradiotherapy was 100%, and the overall efficacy after the end of chemoradiotherapy was also 100%. Three-year overall survival (OS), distant metastasis-free survival (DMFS), locoregional control (LRC) and progression-free survival (PFS) rates were 85.6, 81.9, 97.8 and 79.5%, respectively. The main adverse reactions were hematologic toxicity, particularly neutropenia (100%), anemia (88.9%) and thrombocytopenia (68.9%). Patients developed a relatively low degree of mucositis and vasculitis. Chronic toxicity was mainly grade I-II radiation-induced xerostomia (18 cases). There were 11 cases of hearing loss and 4 cases of neck skin fibrosis. No cases of treatment-related death and radiation-induced cranial nerve damage or trismus were observed.In N3 stage NPC, induction chemotherapy and sequential Nimotuzumab plus concurrent chemoradiotherapy yielded an excellent survival benefit, and the toxicities were tolerable. Distant metastasis was the main cause of treatment failure.

6050 Background: A Phase II, randomized, prospective, multicentric trial was conducted to evaluate the efficacy and safety of Endostar plus radiotherapy in patients with low-risk local advanced nasopharyngeal carcinoma (NPC). This study reported the preliminary results of NCT02237924. Methods: From 09/2014 to 08/2016, patients with low-risk local advanced NPC were randomly treated with Endostar plus radiotherapy (ERT group, n=60) and concurrent chemoradiotherapy (CCRT group, n=60). Primary endpoint was the 5-year overall survival (OS) rate. The secondary endpoints were 3-year OS rate, progression free survival (PFS) rate, loco-regional recurrence free survival (LRRFS) rate and distance metastasis free survival (DMFS) rate. Results: After a median follow-up of 47 months, 3-year OS rate were 93.2% and 79.3% (p=0.032), 3-year PFS rate were 89.8% and 70.6% (p=0.011), 3-year DMFS rate were 93.2% and 80.7%, in two groups, respectively (P=0.042). 3-year LRRFS rate were 96.6% and 92.0% in two groups, respectively (but P=0.565). For short-term curative effects, CR rate were 71.2% and 60.0% for primary tumor, 74.6％and 63.3％for cervical lymph nodes, in two groups, respectively (P < 0.05). Moreover, the incidences of adverse events were significantly lower in ERT group compared with in CCRT group. The grade 3/4 Hyponatraemia (0 [0%] vs 3 [5%], p=0·04), the grade 1/2 vomiting (10 [16.7%] vs 52 [86.7%], p=0.000), dry mouth (45 [75.0%] vs 56 [93.3%], p=0.012), leukopenia (22 [36.7%] vs 42 [70.0%], p=0.000) and weight loss (30 [50.0%] vs 45 [75.0%], p=0.005). No patients died of treatment-related causes. Conclusions: OS, PFS, and DMFS rates can be improved, adverse events be reduced, with better tolerability, by Endostar plus radiotherapy, when compared to concurrent chemoradiotherapy for local advanced low-risk NPC. Clinical trial information: NCT02237924. [Table: see text]

Rubredoxins (Rds), like those from Pyrococcus furious (Pf), have largely been found to be expressed in Escherichia coli (E. coli) as a mixture of different N-terminal forms, which may affect the properties of the protein. The typical procedures for the purification of Rds are cumbersome and usually with low yield. We present herein a streamlined purification strategy based on the reversed-phase high performance liquid chromatography (RP-HPLC), which offers high yield and high resolution after simply one-step purification following pre-treatment. We also show that RP-HPLC can be a valuable tool to gain information related to the thermal decomposition pathway of Pf-Rds.

A new 2D Mn-MOF (Mn-PRCA, PRCA = pyrazine 2,3-dicarboxylic anhydride) is constructed and used as a host for the loading of Ni2+ through post-synthetic modification method (PSM). Then the bimetal MOF(Ni@Mn-PRCA) is served as template for the synthesis of Ni0.4Mn1.6P by the phosphorization route. The obtained Ni0.4Mn1.6P is used as electrode material and exhibit a large specific capacitance of 1060 F/g at 1 A g and a capacitance retention of 75 % after 2000 cycles). In addition, an asymmetric device Ni0.4Mn1.6P // AC (activated carbon) is also assembled and shows an energy density of 21.1 W h kg −1 at the power density of 799.6 kW kg -1 under a stable working voltage of 1.6 V. This is the first time that PSM technique is applied in electrochemical application and bimetal phosphide derived from a new MOF is used as electrode materials for supercapacitor.

To evaluate the efficacy and safety of the chemotherapy program of docetaxel combined with lobaplatin for Chinese patients with pulmonary and hepatic metastasis of nasopharyngeal carcinoma (NPC). This study included 37 NPC patients with pulmonary and hepatic metastasis. The chemotherapy program included docetaxel (75 mg/m, day 1) plus lobaplatin (30 mg/m, day 1). Cycle repetition was every 21 days. Patients were monitored for 7-41 months, with a median follow-up duration of 18 months. The total efficiency of this group was 67.6% and the disease control rate was 81.1%. The median progression-free survival was 9.4 months (95% confidence interval, 6.8-14.3 months), the median overall survival was 18.3 months (95% confidence interval, 13.7-22.8 months), and the 2-year survival rate was 37.8%. The main hematological toxicities were leukopenia (91.9%), anemia (81.1%), and thrombocytopenia (70.3%); other adverse reactions were mild. Changes in Epstein-Barr-DNA levels can basically reflect the dynamic changes in the efficacy of chemotherapy. Docetaxel combined with lobaplatin has a favorable outcome for the treatment of pulmonary and hepatic metastatic NPC. It has been a convenient regimen with tolerable toxicity.

A new cadmium metal–organic framework [Cd(NIPA)(CH3CH2OH)3] (NIPA = 5-nitroisophthalic acid) has been assembled and served as precursor to fabricate nanoporous nitrogen doped carbon material via carbonization process under 900 °C (NC900). The obtained NC900 shows high capacitance (367 F g−1 at 1 A/g), good cycling life (95% of initial capacitance after 3000 cycles). Moreover, NC900//NC900 supercapacitor device is assembled and shows energy density of 6.3 Wh kg−1 with a current density of 1 A/g and the capacitance retention maintains 65% at 0.5 A g−1 after 3000 cycles). The results obtained provide a facile way to prepare carbon material (MOF is used as precursor) for energy-storage devices. For the first time, the heteroatom doped nanoporous carbon material based on a new Cd MOF is served as supercapacitor materials.

A Zinc metal–organic framework (MOF) is prepared and as a host to incorporated with Eu3+ ions (2,6-Naphthalenedicarboxylic acid is used as the ligand) by a solvothermal method and post-synthetic modification method (PSM). The obtained luminescent material Eu(3 + )@Zn-NDC is characterized by XRD, IR, TGA and SEM. Eu(3+)@Zn-NDC show three sensing channels for Cr3+, three good linearities exist ranging from 1 × 10−3 to 7.5 × 10−5 mol/L. The results show that the Eu(3+)@Zn-NDC exhibits selective, sensitive and quantitative response to Cr3+ and the sensing range is broaden to meet practical application. Its sensing mechanism is discussed. This is first time that Eu(3+)@ Zn-NDC is promising three-channel sensor for Cr3+ ions.

6036 Background: We conducted a multicenter prospective study (NCT02575547) to investigate the association between longitudinal nutritional status and survival in locally advanced nasopharynx cancer (LA-NPC) treated with induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT). Methods: All patients with biopsy-proven LA-NPC and planned for IC-CCRT were recruited from ten institutions. IC entailed 2 cycles of docetaxel 75mg/m2/3w and cisplatin 75mg/m2/3w; CCRT entailed 2-3 cycles cisplatin 100mg/m2/3w and IMRT (70-72Gy/30-32fr). Study parameters included weight loss (WL), % of ideal body weight (%IBW), body mass index (BMI), nutrition risk screening 2002 (NRS2002), patient-generated subjective global assessment (PG-SGA), and EORTC QLQ-C30 that were collected at the following time-points: baseline (T1), 1 w pre-2nd IC (T2), 1 w pre-CCRT (T3), 4 w mid-CCRT (T4), end-CCRT (T5), 3 mo post-CCRT (T6), 1 y post-CCRT (T7), 2 y post-CCRT (T8). Results: 186 patients were recruited; 171 were eligible for analysis. Median follow-up was 35.8 mo (range 12.3-46.1 mo). Compliance rates were 97.7% (167/171) and 87.7% (150/171) for IC and CCRT, respectively; all except one completed RT. Longitudinal assessment indicated the worst nutritional status at T5, followed by recovery at T8: 27.1% with %IBW 0.05 for all). However, nutritional parameters at T5 were significantly associated with survival; %IBW

Background: Although an elevated hemoglobin A1c (HbAc1) level is an independent predictor of worse survival in patients with both digestive cancer and diabetes mellitus, its relationship to short-term prognosis in these patients has not been addressed. This study assessed this relationship in gastrointestinal cancer (GIC) patients with type 2 diabetes mellitus (T2DM). Methods: A retrospective review of patients with GIC with or without T2DM from 2004 to 2014 was performed. Patients with T2DM were grouped according to HbA1c level, either normal (mean < 7.0%) or elevated (mean ≥ 7.0%). Age- and sex-matched GIC patients without T2DM served as controls. Results: One hundred and eighteen patients aged 33 - 81 years with T2DM met the study eligibility criteria; 51 were in the normal HbA1c group, and 67 were in the elevated HbA1c group. The 91 patients in the non-T2DM group were randomly selected and matched to the T2DM group in terms of admittance date, age, and sex. There was a trend toward a higher 180-day mortality rate in the T2DM group compared with the non-T2DM group (15.3% vs. 7.7%, P = 0.095) and in the elevated HbA1c group compared with the normal HbA1c group (19.4% vs. 9.8%, P = 0.151); however, the differences were not significant. The duration of the hospital stay was longer in patients with T2DM than in those without T2DM (13.2 vs. 8.9 days, P < 0.05) and in patients with elevated versus normal HbA1c levels (14.5 vs. 11.4 days, P < 0.05). Diabetic GIC patients with elevated HbA1c levels had significantly more total postoperative complications than those with normal HbA1c levels (25.4% vs. 9.8%, P < 0.05). In multivariate regression analyses, short-term adverse outcomes were strongly associated with elevated HbA1c levels (odds ratio (OR): 5.276; 95% confidence level (CI): 1.73 - 16.095; P < 0.05) and no strict antidiabetic treatment (OR: 7.65; 95% CI: 2.49 - 23.54; P < 0.001). Conclusion: An elevated level of HbA1c significantly correlated with and was an independent predictor of short-term adverse outcomes in GIC patients with T2DM. J Clin Med Res. 2017;9(4):303-309 doi: https://doi.org/10.14740/jocmr2607w

To evaluate the efficacy and safety of lobaplatin combined with docetaxel as neoadjuvant chemotherapy followed by concurrent lobaplatin with intensity-modulated radiotherapy (IMRT) for high-risk positive lymph node (N+) nasopharyngeal carcinoma (NPC).This study enrolled 37 primary high-risk N+ NPC patients. The neoadjuvant chemotherapy program consisted of lobaplatin (30 mg/m(2), day 1) plus docetaxel (75 mg/m(2), day 1) for two cycles, 3 weeks apart. Concurrently with IMRT, patients received a chemotherapy program of lobaplatin 50mg/m(2). Cycle repetition was every 21 days. The IMRT doses were planning target volume (PTV) 68-72 Gy for gross disease in the nasopharynx, and 66-70 Gy for positive lymph nodes in 33 FRACTIONS. The doses for high risk and low risk region PTV were 59.4 Gy in 33 fractions and 50.4 Gy in 28 fractions.The median follow-up duration was 31 months (range 4-52). The 3-year overall survival (OS) was 74.3%. The 3-year distant metastasis-free survival (DMFS) was 67.4%. The 3-year locoregional relapse-free survival (LRFS) was 91.5%, and the 3-year progression-free survival (PFS) was 61.2%. The efficiency of short-term effects of neoadjuvant chemotherapy and chemoradiotherapy were 83.8% and 100.0%, respectively. Serious acute toxicities observed were neutropenia (97.3%), thrombocytopenia (83.8%) and anemia (81.1%).In patients with high-risk N+ NPC, lobaplatin combined with docetaxel neoadjuvant chemotherapy followed by concurrent lobaplatin with IMRT yielded excellent short-term results with mild and tolerable toxicities.

Influences of waste materials containing tungsten on melting and crystallization of glass-ceramics are discussed in this article. High temperature melting, nucleation and crystallization of glass-ceramics were explored by means of DTA, XRD and SEM. The high temperature melting performance of glass-ceramics ingredients can be effectively improved by mixing the right amount of waste materials containing tungsten. But the additive amount should be properly controlled, the mixing content of waste materials containing tungsten should be a range of 0.5 ~ 2.0 %. In the experiment of glass-ceramics ingredients system, the molten softening temperature of base glass powder reduced about 20 ℃ by adding 1 % waste materials containing tungsten, and the nucleation temperature reduced about 15 ℃. The nucleation and crystallization performance of glass-ceramics mineral crystals can be promoted by mixing the right amount of waste materials containing tungsten. That is helpful to improve the quality of glass-ceramics products.

Background: The purpose of this study was to analyze the efficacy and safety of concurrent chemoradiotherapy combined with Nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma (NPC). Methods: This study included 49 low-risk T4 stage NPC patients treated with concurrent chemoradiotherapy plus Nimotuzumab. The IMRT doses were planning target volume (PTV) 70–72 Gy for gross disease in the nasopharynx, and 66–70 Gy for positive lymph nodes. The doses for high risk and low risk region PTV were 60–62 Gy and 54–56 Gy in 31-33 fractions. All patients received a chemotherapy program consisting of Cisplatin 100mg/m2, day 1, Q3w and were treated by Nimotuzumab (Nimotuzumab 200mg, iv, Qw). Results: All 49 patients completed at least two cycles of chemotherapy and seven weeks of Nimotuzumab. The total efficiency of therapy was 100.0%. The 3-year overall survival (OS), distant metastasis-free survival (DMFS), local-regional control (LRC) and progression-free survival (PFS) rates were 89.7%, 87.8%, 97.9% and 85.7%, respectively. No regional lymph node recurrence was detected. The most serious acute toxicity was mucositis, with prevalence of Grades 0 to IV being 0.0%, 57.1%, 34.7%, 8.2%, and 0.0%, respectively. Late toxicity manifested as Grades I and II xerostomia in 32 and 10 patients. Conclusion: In patients with low-risk T4 stage NPC, concurrent chemoradiotherapy combined with Nimotuzumab yielded an excellent local control rate, and the toxicities were mild and tolerable. Distant metastasis was the main cause of treatment failure.

Emission pollution and prevention measures of Pb during cement calcination were discussed. The content of Pb and the variation of composition were explored by means of atomic absorption spectroscopy (AAS) and X-ray diffraction. The results show that a number of Pb emits during cement calcination, F and Cl promote the emission of Pb, and Pb is enriched in kiln dust. The smaller the particle of kiln dust, the higher the content of Pb. When utilizing the raw materials with a high content of Pb, a more efficient dust collector should be used and the kiln dust should be used as the addition of cement. Pb in clinker is enriched in the intermediate phase. The reduction of silica modulus is useful to increase the solidification content of Pb in clinker. The solidification content of Pb in calcium sulphoaluminate mineral is higher than that in calcium aluminate mineral.

To explore the clinical efficacy of radiotherapy combined with concurrent combination chemotherapy in the treatment of patients with advanced nasopharyngeal carcinoma (NPC).Two hundred patients with stage III/IV NPC were randomly allocated into the treatment group (N=100) and the control group (N=100). Patients in the control group received conventional fractionated radiotherapy, while patients in the treatment group received conventional fractionated radiotherapy combined with concurrent combination chemotherapy with cisplatin and 5-fluorouracil (5-FU). Short-term efficacy, radiotherapy toxicity, shortand long-term survival were compared.The short-term response rate of the treatment group was 96%, which was significantly higher than that of the control group (87%, p0.05). The local radiation toxicity of the treatment group was similar to that of the control group p0.05), but the hematological and gastrointestinal toxicities were significantly higher in the treatment group p0.05). The 1-, 3- and 5-year overall survival rates were 87, 80, and 76%, respectively, in the treatment group and 74, 64, and 51%, respectively, in the control group, significantly favoring the treatment group p0.05).Radiotherapy with concurrent combination chemotherapy can improve the prognosis of patients with advanced NPC but at the cost of significant toxicity.

6063 Background: A prospective, randomized, and multicentric phase II study was performed to evaluate the short-term efficacy and safety of Endostar plus intensity-modulated radiotherapy (IMRT) versus concurrent chemoradiotherapy(CCRT) in locally advanced low-risk nasopharyngeal carcinoma(NPC). Methods: From September 2014 to August 2016, 120 patients with low-risk NPC at stages III-IVa from 9 centers were randomly divided into experimental group (Endostar plus radiotherapy (ERT); n = 60) and control group (CCRT; n = 60). ERT patients were given Endostar (7.5 mg/m2/day) by continuous intravenous infusion (CIV) from 5 days before radiotherapy for consecutive 10 days for 2 cycles with an interval of 14 days. Then, ERT patients received 2 cycles of 10 days of maintenance treatment with Endostar after radiotherapy. The CCRT patients were given cisplatin (100 mg/m2) on days 1, 22, and 43 for 3 cycles. Immediate and 3-month efficacy and adverse effects were evaluated between the two groups. ClinicalTrials registration number was NCT02237924. Results: All patients were eligible for toxicity and response analysis. Regarding immediate efficacy, the complete response(CR) rates were 45.0% for ERT arm and 33.3% for CCRT arm in nasopharynx (P = 0.190), and 43.3% for ERT arm and 36.7% for CCRT arm in regional nodes (P = 0.456). Three months after RT, the CR rates were 71.2% for ERT arm and 60.0% for CCRT arm in nasopharynx (P = 0.151), and 74.6% for ERT arm and 63.3% for CCRT arm in regional nodes (P = 0.172). The rate and severity of leukopenia, hemoglobin reduction and thrombocytopenia in ERT arm were significantly lower than CCRT arm (P < 0.01). The occurrence rates of Xerostomia, oral mucositis, nausea / vomiting, constipation and weight loss in ERT arm were significantly lower than those in CCRT arm (P < 0.01). Conclusions: The present study demonstrates that ERT has similar short-term efficacy on locally advanced low-risk NPC compared with CCRT, but the acute adverse effects of ERT are fewer, and the compliance and tolerability of patients are better. Clinical trial information: NCT02237924.